AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33355910 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Number of subjects: 38
Study 33355910 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 100 mg
Number of subjects: 38
Study 33355910 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 200 mg
Number of subjects: 38
Study 33355910 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 100 mg (multiple dose for 10 days)
Number of subjects: 38
Study 33355910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 32120018 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg testosterone
Number of subjects: 140
Study 32120018 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 140
Study 35973791 — intervention group
Group type: EXPERIMENTAL
Intervention: Early GDM screening (14-20 weeks' gestation)
Number of subjects: 913
Study 35973791 — intervention group
Group type: COMPARATOR
Intervention: Routine GDM screening (24-28 weeks' gestation)
Number of subjects: 913
Study 35973791 — intervention group
Group type: EXPERIMENTAL
Intervention: Early GDM screening
Number of subjects: 913
Study 35973791 — intervention group
Group type: COMPARATOR
Intervention: Routine GDM screening
Number of subjects: 913
Study 33662166 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive medication (AHM)
Number of subjects: 36
Study 33662166 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 36
Study 36321501 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg weekly for 12 months
Number of subjects: 280
Study 36321501 — intervention group
Group type: COMPARATOR
Intervention: Placebo-matched tablet
Number of subjects: 280
Study 33996262 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 0
Study 33996262 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 32697957 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitions to failure (RFG, n = 13)
Number of subjects: 36
Study 32697957 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitions not to failure and 50% of the repetitions of the RFG (NFG, n = 12)
Number of subjects: 36
Study 32697957 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitions not to failure with equal training volume of the RFG (ENFG, n = 11)
Number of subjects: 36
Study 34563558 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid fluid at 10 mL.kg‐1 of ideal body weight administered intravenously 30 minutes before BCP
Number of subjects: 49
Study 32048881 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour dietary recall
Number of subjects: 468
Study 32048881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient adequacy ratios from 3-day weighed food records
Number of subjects: 468
Study 35102001 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured contraceptive counselling
Number of subjects: 1295
Study 35102001 — intervention group
Group type: COMPARATOR
Intervention: Standard contraceptive counselling
Number of subjects: 1295
Study 34772367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (PeARS): one antenatal and one postnatal session including support from a non-professional peer, information about local community services, and development of a personalised If-Then plan.
Number of subjects: 126
Study 34772367 — intervention group
Group type: COMPARATOR
Intervention: Control (booklet about local resources)
Number of subjects: 126
Study 32921170 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 autosomal STR markers genotyping using PowerPlex® Fusion 6C multiplex system (Promega)
Number of subjects: 184
Study 32921170 — intervention group
Group type: COMPARATOR
Intervention: Genetic relatedness analysis with non-Muslim populations
Number of subjects: 184
Study 35171948 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered psychoeducational intervention (fertility preservation values clarification tool and guided conversation)
Number of subjects: 0
Study 35171948 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control group (fertility consult)
Number of subjects: 0
Study 35171948 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-centered psychoeducational intervention
Number of subjects: 0
Study 34328655 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametric knockoff filter based on variable importance scores from penalized linear regression model
Number of subjects: 0
Study 34328655 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric knockoff filter based on causal forest variable importance scores
Number of subjects: 0
Study 34328655 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of proposed methods to data from a randomized clinical trial
Number of subjects: 0
Study 32583773 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment T2 (6 billion cfu)
Number of subjects: 30
Study 32583773 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment T1 (3 billion cfu)
Number of subjects: 30
Study 32583773 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-III (Plumpy'nut)
Number of subjects: 30
Study 32583773 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment
Number of subjects: 30
Study 34562410 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatment strategies for MINOCA (specifics not provided)
Number of subjects: 150
Study 34562410 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel biomarkers and modern imaging techniques (heart magnetic resonance imaging and noninvasive testing)
Number of subjects: 150
Study 33760658 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy
Number of subjects: 308
Study 34590519 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 µg
Number of subjects: 52
Study 34590519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 33068347 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated plaster at Dazhui (GV 14) applied 30 min before operation
Number of subjects: 300
Study 33068347 — intervention group
Group type: COMPARATOR
Intervention: Control group received routine heat preservation measures
Number of subjects: 300
Study 35606688 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative depression
Number of subjects: 320
Study 35606688 — intervention group
Group type: COMPARATOR
Intervention: Baseline depression
Number of subjects: 320
Study 33065191 — intervention group
Group type: COMPARATOR
Intervention: HCS-only
Number of subjects: 117
Study 33065191 — intervention group
Group type: EXPERIMENTAL
Intervention: HCS+PAE
Number of subjects: 117
Study 32567586 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation with polyethylene glycol (PEG)
Number of subjects: 100
Study 32567586 — intervention group
Group type: COMPARATOR
Intervention: Preparation with sodium picosulfate
Number of subjects: 100
Study 32567586 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up phone call prior to the study
Number of subjects: 100
Study 36266046 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid treatment with usual care
Number of subjects: 813
Study 36266046 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 813
Study 34819291 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 1: Reminder texts and US$0.50 per day of medication taken
Number of subjects: 0
Study 34819291 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 2: US$0.25 per adherent-day with adaptive reward system and reminder texts if adherence <75%
Number of subjects: 0
Study 34819291 — intervention group
Group type: COMPARATOR
Intervention: Control: Not specified
Number of subjects: 0
Study 32250059 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (0.3 to 0.6 mg/kg)
Number of subjects: 0
Study 32250059 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg)
Number of subjects: 0
Study 32250059 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclinical psilocin (60 ng/mL)
Number of subjects: 0
Study 32315508 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 U/mL (Gla-300)
Number of subjects: 0
Study 32315508 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 0
Study 32315508 — intervention group
Group type: COMPARATOR
Intervention: Gla-300 and IDeg
Number of subjects: 0
Study 35124734 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted RP
Number of subjects: 310
Study 34091625 — intervention group
Group type: EXPERIMENTAL
Intervention: Education through specifically-designed tools
Number of subjects: 58
Study 34091625 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 58
Study 32811527 — intervention group
Group type: EXPERIMENTAL
Intervention: Periacetabular Osteotomy with hip arthroscopy (experimental group)
Number of subjects: 52
Study 32811527 — intervention group
Group type: COMPARATOR
Intervention: Isolated Periacetabular Osteotomy (control group)
Number of subjects: 52
Study 35952408 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotion training
Number of subjects: 30
Study 35952408 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 30
Study 32522756 — intervention group
Group type: EXPERIMENTAL
Intervention: agalsidase‐beta (1.0 mg/kg), regular‐dose group, n=17
Number of subjects: 78
Study 32522756 — intervention group
Group type: EXPERIMENTAL
Intervention: agalsidase‐alfa (0.2 mg/kg), switch group, n=22
Number of subjects: 78
Study 32522756 — intervention group
Group type: EXPERIMENTAL
Intervention: agalsidase‐beta after agalsidase‐alfa, re‐switch group, n=39
Number of subjects: 78
Study 32888906 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulated dual task (mathematical task) during prone bridging test
Number of subjects: 14
Study 32888906 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulated dual task (mathematical task) during Biering-Sorensen test
Number of subjects: 14
Study 32888906 — intervention group
Group type: COMPARATOR
Intervention: Single task (without cognitive condition) during Biering-Sorensen test
Number of subjects: 14
Study 34528692 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session telehealth intervention for speech-language therapy
Number of subjects: 0
Study 34528692 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaged communication partner group
Number of subjects: 0
Study 34528692 — intervention group
Group type: COMPARATOR
Intervention: Check-in group (randomized control)
Number of subjects: 0
Study 32203040 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Brain Metastases Detection Framework using gadolinium-enhanced T1-weighted 3D MRI
Number of subjects: 158
Study 32203040 — intervention group
Group type: COMPARATOR
Intervention: State-of-the-art approaches for larger lesions
Number of subjects: 158
Study 35944873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooking Matters for Diabetes (CMFD) intervention
Number of subjects: 13
Study 33823208 — intervention group
Group type: EXPERIMENTAL
Intervention: Low temperature (4 °C)
Number of subjects: 80
Study 33823208 — intervention group
Group type: COMPARATOR
Intervention: Room temperature (25 °C)
Number of subjects: 80
Study 33823208 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed (37 °C)
Number of subjects: 80
Study 32384426 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus tablet (NPC‐12T)
Number of subjects: 16
Study 32384426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 34056830 — intervention group
Group type: EXPERIMENTAL
Intervention: JW-100 (CBD plus aspartame)
Number of subjects: 57
Study 34056830 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD only
Number of subjects: 57
Study 34056830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 32667956 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Otago Exercise Program (home-based balance and strength exercises)
Number of subjects: 52
Study 32667956 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group (continuation of usual lifestyle)
Number of subjects: 52
Study 34282872 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated low-intensity intervention program (additional visits, health education, enhanced communication, weekly SMS reminders)
Number of subjects: 172
Study 34282872 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (control group)
Number of subjects: 172
Study 33334875 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 13
Study 33334875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 32543698 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual experiences, values, and beliefs; religious practices; overall self‐ranking of spirituality's importance
Number of subjects: 126
Study 32543698 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling God's presence daily
Number of subjects: 126
Study 32543698 — intervention group
Group type: EXPERIMENTAL
Intervention: Considering oneself very religious
Number of subjects: 126
Study 32543698 — intervention group
Group type: EXPERIMENTAL
Intervention: Considering oneself very spiritual
Number of subjects: 126
Study 32543698 — intervention group
Group type: COMPARATOR
Intervention: Spiritual scales
Number of subjects: 126
Study 36137472 — intervention group
Group type: EXPERIMENTAL
Intervention: OS + NNS
Number of subjects: 130
Study 36137472 — intervention group
Group type: EXPERIMENTAL
Intervention: OS + NNS + T/K
Number of subjects: 130
Study 36137472 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 130
Study 33563321 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-oxoproline
Number of subjects: 0
Study 33563321 — intervention group
Group type: EXPERIMENTAL
Intervention: dihomo-linoleate (20:2n6)
Number of subjects: 0
Study 33563321 — intervention group
Group type: EXPERIMENTAL
Intervention: p-acetamidophenylglucuronide
Number of subjects: 0
Study 35396297 — intervention group
Group type: COMPARATOR
Intervention: 5 µg vaccine (Stage I)
Number of subjects: 368
Study 35396297 — intervention group
Group type: COMPARATOR
Intervention: 3 µg vaccine (Stage I)
Number of subjects: 368
Study 35396297 — intervention group
Group type: COMPARATOR
Intervention: 5 µg vaccine (Stage II)
Number of subjects: 368
Study 35396297 — intervention group
Group type: COMPARATOR
Intervention: 5 µg vaccine (Phase II)
Number of subjects: 368
Study 35396297 — intervention group
Group type: COMPARATOR
Intervention: cVNT (Phase I)
Number of subjects: 368
Study 35396297 — intervention group
Group type: COMPARATOR
Intervention: cVNT (Phase II)
Number of subjects: 368
Study 35301422 — intervention group
Group type: EXPERIMENTAL
Intervention: Icon
Number of subjects: 174
Study 35301422 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinpro with HCl pretreatment
Number of subjects: 174
Study 35301422 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid (PA) + Clinpro
Number of subjects: 174
Study 35301422 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoric acid (PA) + Aegis
Number of subjects: 174
Study 35301422 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloric acid (HCl) + Clinpro
Number of subjects: 174
Study 35301422 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochloric acid (HCl) + Aegis
Number of subjects: 174
Study 35301422 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 174
Study 32445498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab 225 mg monthly
Number of subjects: 0
Study 32445498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab 675 mg quarterly
Number of subjects: 0
Study 32445498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35793879 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist-ankle acupuncture
Number of subjects: 64
Study 35793879 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 64
Study 33737422 — intervention group
Group type: EXPERIMENTAL
Intervention: eCDS tool for suspected cancer
Number of subjects: 530
Study 33737422 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 530
Study 32433779 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment, 2%, applied twice daily
Number of subjects: 244
Study 35608178 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST simulator training (low-fidelity)
Number of subjects: 28
Study 35608178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 35608178 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Experimental and Control)
Number of subjects: 28
Study 35608178 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (FAST simulator training)
Number of subjects: 28
Study 32931877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogue (NA) treatment
Number of subjects: 83
Study 32931877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon‐alfa2a (PEG‐IFN) treatment
Number of subjects: 83
Study 32931877 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without HBsAg loss)
Number of subjects: 83
Study 35693746 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose: 1 μg/kg over 10 min; maintenance dose: 0.2‐0.7 μg/kg/h)
Number of subjects: 40
Study 35693746 — intervention group
Group type: COMPARATOR
Intervention: Propofol (loading dose: 75 μg/kg over 10 min; maintenance dose: 12.5‐75 μg/kg/min)
Number of subjects: 40
Study 32780820 — intervention group
Group type: EXPERIMENTAL
Intervention: Trephine drill
Number of subjects: 42
Study 32780820 — intervention group
Group type: COMPARATOR
Intervention: Conventional drilling technique
Number of subjects: 42
Study 34476645 — intervention group
Group type: EXPERIMENTAL
Intervention: Reparixin (R) in combination with paclitaxel (P) 80 mg/m2 on days 1, 8, 15 of 28-day cycles.
Number of subjects: 123
Study 34476645 — intervention group
Group type: COMPARATOR
Intervention: Placebo in combination with paclitaxel (P) 80 mg/m2 on days 1, 8, 15 of 28-day cycles.
Number of subjects: 123
Study 34476645 — intervention group
Group type: EXPERIMENTAL
Intervention: Reparixin (R) + paclitaxel (P)
Number of subjects: 123
Study 34476645 — intervention group
Group type: COMPARATOR
Intervention: Placebo + paclitaxel (P)
Number of subjects: 123
Study 32712017 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN XT transcatheter heart valve (THV)
Number of subjects: 199
Study 35333027 — intervention group
Group type: EXPERIMENTAL
Intervention: FIVE futsal neuromuscular warm-up program, performed 3 times per week for 6 weeks, in addition to regular futsal training.
Number of subjects: 95
Study 35333027 — intervention group
Group type: EXPERIMENTAL
Intervention: FIVE futsal neuromuscular warm-up program.
Number of subjects: 95
Study 33930329 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 33930329 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 0
Study 33930329 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 receptor antagonists
Number of subjects: 0
Study 33930329 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids
Number of subjects: 0
Study 33979736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomograms developed to predict overall survival (OS) and cancer-specific survival (CSS)
Number of subjects: 1781
Study 33979736 — intervention group
Group type: COMPARATOR
Intervention: Nomograms compared to the Tumor-Node-Metastasis (TNM) staging system
Number of subjects: 1781
Study 36434164 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (aRT) with 60-72 Gy ± ADT
Number of subjects: 3510
Study 36434164 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (aRT)
Number of subjects: 3510
Study 34555048 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced self-care with disinfectant using a custom-fabricated prescription tray applied twice a day
Number of subjects: 110
Study 34555048 — intervention group
Group type: COMPARATOR
Intervention: Standard care for periodontal diseases
Number of subjects: 110
Study 34554352 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) belimumab 10 mg/kg
Number of subjects: 36
Study 34554352 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (SC) belimumab 200 mg
Number of subjects: 36
Study 32977137 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic enoxaparin
Number of subjects: 20
Study 32977137 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic anticoagulation
Number of subjects: 20
Study 35689904 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS combined with DAF (1 mA)
Number of subjects: 50
Study 35689904 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS combined with DAF
Number of subjects: 50
Study 33892676 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic signature based nomogram using 23-RNA signatures
Number of subjects: 300
Study 33892676 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic signature based nomogram
Number of subjects: 300
Study 34399976 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal planning skills
Number of subjects: 108
Study 34399976 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime routines
Number of subjects: 108
Study 32725799 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 80
Study 32725799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 36197647 — intervention group
Group type: EXPERIMENTAL
Intervention: Genicular nerve block (GNB)
Number of subjects: 104
Study 36197647 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular triamcinolone (TA)
Number of subjects: 104
Study 33609174 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast (ready‐to‐eat‐cereal [RTEC] and milk, up to 70 g of cereal and 300 ml of milk)
Number of subjects: 234
Study 33609174 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast (ready‐to‐eat‐cereal [RTEC] and milk)
Number of subjects: 234
Study 33609174 — intervention group
Group type: COMPARATOR
Intervention: No Breakfast
Number of subjects: 234
Study 35289296 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple Therapy (TT)
Number of subjects: 151
Study 35289296 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG/3TC
Number of subjects: 151
Study 35289296 — intervention group
Group type: EXPERIMENTAL
Intervention: DRVc/3TC
Number of subjects: 151
Study 32307061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0